TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the ...
ProMIS Neurosciences Inc. PMN shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), ...
Fintel reports that on May 12, 2025, Maxim Group initiated coverage of ProMIS Neurosciences (NasdaqCM:PMN) with a Buy recommendation. As of May 7, 2025, the average one-year price target for ProMIS ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
Promis Neurosciences Inc. has submitted an IND application to the FDA for PMN-310 for the treatment of Alzheimer’s disease. PMN-310 is a monoclonal antibody designed to be highly selective for toxic ...
Researchers have found a novel, pathogenic entity that is a fundamental link between chronic inflammation and tissue destruction in lungs of patients with COPD. These exosomes from activated ...
As highlighted above, PMN are a vital component of the innate immune system and comprise a critical component of the army of first responsers to sites of inflammation. 1, 2 Although it is clear that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results